Truist upgrades Evolent Health stock rating on valuation, 2027 outlook

Truist upgraded Evolent Health (EVH) to Buy with a $6.00 price target, citing undervaluation and improved 2027 outlook. The stock is down 30% week-to-date, trading at $3.43. Truist expects 2027 adjusted EBITDA midpoint to be at least $150M. EVH reported Q3 earnings meeting profit forecasts, with revenue at $725.4M and adjusted EBITDA at $34.3M, exceeding prior outlook.

Original reporting
Published Nov 20, 2026, 5:54 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 20, 2026, 6:07 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$EVH
Bullish
high confidence
Mentioned
$EVH
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$EVHBullishMed
01

Why it matters

The buy rating and $6 target could attract new buying interest, supporting a short‑term rally.

02

Market read

Analyst upgrade provides a fresh catalyst for EVH, offering a potential entry point for traders.

03

What to watch

Potential downside from Medicare‑For‑All legislation and Medicaid attrition could pressure earnings.

Relevance 7/10Novelty 7/10Timing: today

Background

Truist Securities highlighted valuation gaps and a more favorable 2027 EBITDA outlook as the basis for the upgrade.

Company-level read

Ticker impact

$EVHBullishHigh confidence
Context

Truist upgraded Evolent Health (EVH) to Buy from Hold with a $6 price target, citing improved 2027 outlook and valuation.

Expected impact

upward pressure as investors price in the buy rating and target.

Evidence & confidence

Analyst upgrade with concrete valuation and guidance range is a fresh catalyst that can move the stock.

Market effects

May lift sentiment in the healthcare services sector as a peer receives a buy rating.

Limited to U.S. markets; no broader regional effect.

Minimal global impact beyond EVH investors.

Counterpoint

The upgrade may be premature if Medicaid policy risks materialize, potentially limiting upside.

Key entities

  • Truist Securities

    Research firm issuing the upgrade.

  • Evolent Health

    Healthcare technology firm receiving the upgrade.

Related articles

$EVHMedAI 8/10

EVH Q3 2026 deep dive: ongoing AI investment and customer expansion shape outlook

EVH reported Q3 2026 revenue of $725.4M (51.3% YoY growth, in line with estimates) and adjusted EPS of $0.06 (in line). Adjusted EBITDA was $34.26M, beating estimates by 3.1%. The company reconfirmed full-year revenue guidance of $2.65B and raised EBITDA guidance to $132.5M. Sales volumes fell 4.2% YoY, while operating margin declined to -0.9%. EVH expanded its AI platform, Oncology care, and National payer scale, citing cost savings and margin expansion potential.

$EVHMed

Evolent Health, Inc. Q3 2026 Earnings Call Summary

Evolent Health reported 11% sequential revenue growth driven by Highmark Performance Suite and contractual adjustments. MER improved to 93%. Management prioritizes margin expansion and cash generation, with oncology expected to represent over 70% of revenue by 2027. AI platform scales, processing 1M cases annually. Management reiterated 2027 Adjusted EBITDA confidence of $150M+ and plans $50M debt reduction by 2026 year-end.

$EVHMedAI 8/10

Evolent Health (EVH) Q3 2026 Earnings Call Transcript

Evolent Health (EVH) reiterated its full-year revenue guidance of $2.6B-$2.7B and raised Adjusted EBITDA guidance to $130M-$135M. The company reported customer contract renewals and expansions, including a 4-year renewal with its largest Surgical Management customer and expansions in oncology and specialty services.

$EVHMed

Evolent Health: Q3 Earnings Snapshot

Evolent Health (EVH) reported a Q3 loss of $23.6M, or 21 cents per share, with adjusted earnings of 6 cents per share, meeting expectations. Revenue was $725.4M, below the $734.3M forecast. The company expects full-year revenue between $2.6B and $2.7B.